News Release

Cleanascite™ Employed to Help Determine Role of Lipogenesis in Pulmonary Arterial Hypertension

MONMOUTH JUNCTION, NJ , August 29, 2022 -- Biotech Support Group reports on an article, describing the simplicity and efficiency of their lipid clearance sample preparation technology to help determine the role of lipogenesis in a cell response study of pulmonary arterial vascular smooth muscle cells. The citation is:

Jiang, Lifeng, et al. "Akt-Dependent Glycolysis-Driven Lipogenesis Supports Proliferation and Survival of Human Pulmonary Arterial Smooth Muscle Cells in Pulmonary Hypertension." Frontiers in medicine 9 (2022).

Hyper-proliferation of pulmonary arterial vascular smooth muscle cells (PAVSMC) is an important pathological component of pulmonary vascular remodeling in pulmonary arterial hypertension (PAH). Lipogenesis is linked to numerous proliferative diseases, but its role in PAVSMC proliferation in PAH remains to be elucidated. The study aimed to evaluate the status and role of lipogenesis in PAH PAVSMC proliferation and survival. The article states “ To achieve the lipid-deprived cell culture condition, cell culture grade fetal bovine serum (FBS) and BSA were delipidated using Cleanascite ™ … Briefly, Cleanascite ™ was added to the FBS or BSA (1:4 volume ratio). The mixture was incubated for four hours at 4°C with gentle shaking and centrifuged at 16,000 g for 10 min. Supernatant was collected, then a second dose of Cleanascite ™ Lipid Removal Reagent was added (1:4 volume ratio), and incubation and centrifugation steps were repeated as described above. The supernatants, consisting of lipid depleted FBS or BSA, were then used as cell culture media supplements to prepare lipid-depleted media.”. The study found that lipid accumulation detected in PAH PAVSMC was preserved in media deprived from exogenous lipids, indicating that PAH PAVSMC have an ability to generate lipids de novo. Importantly, PAH PAVSMC, in contrast to control cells, demonstrated increased growth not only in serum-deprived media, but in lipid-deprived serum-deprived media. The authors conclude that these data demonstrate that human PAH PAVSMC have up-regulated lipogenesis, which is supported in an Akt- and glycolysis-dependent manner and is required for increased proliferation and survival.

“We now have over twenty references, showing that Cleanascite™ was used to help identify a characteristic feature of in vitro cell response. Unlike alternative lipid-depletion methods that use solvents, Cleanascite™ is an aqueous suspension product and so it is very compatible with cellular models of disease. This ultimately helps with investigations such as this, whereby the cells require fetal bovine serum for growth, but the exogenous lipids need to be removed as part of the lipid-depleted media control.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

To download whitepaper entitled “ Cleanascite™ - Lipid Removal and Cell Response Applications ”, visit:

https://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/CleanasciteCellResponseReferenceApplications113021.pdf

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.

For Business Development , contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com